Browse by Audience
Skip to content
Papers of the Week
Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans.
Authors
Abstract
Lasmiditan demonstrated superiority to placebo in the acute treatment of migraine in adults with moderate/severe migraine disability in two similarly designed Phase 3 trials, SAMURAI and SPARTAN. Post-hoc integrated analyses evaluated the efficacy of lasmiditan in patients who reported a good or insufficient response to triptans and in those who were triptan naïve.